Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Registration Number
- NCT00568984
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 324
Inclusion Criteria
- Type 2 diabetes for at least 3 months
- No previous treatment for diabetes
- HbA1c between 7.0-12.0%
- Body Mass Index (BMI) between 19.0-40.0 kg/m2
Exclusion Criteria
- Type 1 diabetes
- Known unstable/untreated proliferative retinopathy
- Uncontrolled treated/untreated hypertension
- Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c after 16 weeks of treatment
- Secondary Outcome Measures
Name Time Method Glucose profiles Quality of life assessment Treatment satisfaction Hypoglycaemic events Adverse events
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇹🇭Bangkok, Thailand